Motzer et al identified 3 risk factors for predicting survival in previously treated patients with metastatic renal cell carcinoma being evaluated for clinical trials with novel therapeutic agents. The authors are from Memorial Sloan Kettering Cancer Center and the Weil Medical College of Cornell University.
NOTE: These risk factors are a subset of 5 prognostic factors previously reported by Motzer et al in 27.23.06 (above).
Parameters:
(1) Karnofsky performance scale
(2) hemoglobin for gender
(3) corrected serum calcium (for serum albumin)
corrected calcium after Orrell in mg/dL =
= (total serum calcium in mg/dL) - (0.707 * ((serum albumin in g/dL) - 3.4))
|
Parameters |
Finding |
Points |
|
Karnofsky performance scale |
>= 80% |
0 |
|
|
< 80% |
1 |
|
hemoglobin for gender |
male and hemoglobin > 13 g/dL |
0 |
|
|
male and hemoglobin <= 13 g/dL |
1 |
|
|
female and hemoglobin > 11.5 g/dL |
0 |
|
|
female and hemoglobin <= 11.5 g/dL |
1 |
|
corrected serum calcium |
<= 10 mg/dL |
0 |
|
|
> 10 mg/dL |
1 |
number of risk factors =
= SUM(points for all 3 factors)
Interpretation:
• minimum number of risk factors: 0
• maximum number of risk factors: 3
• The prognosis worsens as the number of risk factors increase.
|
Number of Risk Factors |
Median Survival |
|
0 |
22 months |
|
1 |
11.9 months |
|
2 or 3 |
5.4 months |
Purpose: To estimate the survival for a previously treated patient with metastatic renal cell carcinoma using the risk factors of Motzer et al.
Specialty: Hematology Oncology, Surgery, general, Nephrology
Objective: severity, prognosis, stage
ICD-10: C64, C65,
